The Middle-East and Africa Plasma Protein Therapeutics Market is currently valued to be USD 1098.62 Million markets in 2018 held the most dominant share in global market and is estimated to reach USD 1688.36 Million by the end of 2023 with a growth rate of 8.976%. Recent years have witnessed the increased usage of plasma proteins in medical applications. The advancements in technology has made the process for fractionating the protein from plasma more efficient and cost saving and is a huge boost to the market. Reports from suggest that half of the global blood donors are from high income countries which constitutes only 18% of the global population. Rising awareness among individuals regarding the significance of blood donations and government initiatives helped the market to propel the market at a significant rate.
Plasma is a protein rich fluid which is responsible for blood clotting and providing immunity towards diseases. Isolation of these proteins from plasma can be helpful to provide medical therapies which includes immune deficiencies, autoimmune, neurological and bleeding disorders. Plasma protein therapies helps in replacing the deficient or missing proteins and helps the individual to lead a normal life. The therapies involves either the injection or infusion of the biological medicines as a treatment to life-threatening genetic and chronic diseases.
Introduction of new plasma–derived therapies in the market is the key driving force for the market along with a host of others drivers that include increasing prevalence of life threatening diseases involving neurological or immune systems like chronic inflammatory demyelinating polyneuropathy (CIPD), Ideopathic thrombocytopenic purpura (ITP) and other diseases such as Rabies, Hepatitis A&B, Tetanus and varicella. However, there are few hurdles the market must overcome to sustain in the future which including reimbursement issues, stringent regulatory policies and complexities in manufacturing
The Middle-East & Africa Plasma Protein Therapeutics Market is categorised based on type of the product as Albumin, Immunoglobulins, alpha-1 proteinase inhibitors and others. By application, the market is segmented as Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, Secondary Immunodeficiency and others. On the basis of geography region, Middle-East & Africa is categorised as UAE, Saudi Arabia, Israel and others.
The major companies in the plasma protein therapeutic market are Grifols, CSL Behring, , Baxter, Krdrion, China Biologics, Octapharma, Chendu Inst. and Shire Plc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modeling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Immunoglobulins
5.1.2 Albumin
5.1.3 Coagulation Factors
5.1.4 Alpha-1 proteinase inhibitor
5.1.5 Others
5.2 By Application
5.2.1 Hemophilia
5.2.2 Primary Immunodeficiency Disorder
5.2.3 Idiopathic Thrombocytopenic Purpura
5.2.4 Secondary Immunodeficiency
5.2.5 Others
6. Geographical Analysis
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 CSL Behring
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Baxter
8.3 Biotest
8.4 China Biologics
8.5 Grifols
8.6 Kedrion
8.7 Octapharma
8.8 Shire Plc.
8.9 Chengdu Inst.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
